An affiliate of H.I.G. Capital acquired Aspire Pharma Limited, a U.K. provider of niche generic and branded specialty pharmaceuticals, in partnership with Aspire Founder Graham Fraser-Pye. Terms of the transaction were not disclosed.
Founded in 2009, Aspire has a diversified portfolio of over 250 products across various categories, including leading products in urology, ophthalmology, dermatology and central nervous system diseases. Aspire’s current management team will remain in place, with Graham Fraser-Pye taking the role of Chairman.
“H.I.G., with its significant financial and geographic reach, will help us maintain our impressive growth trajectory and take Aspire into another exciting phase for its people and customers,” Fraser-Pye said.
In addition to continuing Aspire’s strong track record of organic growth, future plans include new initiatives such as M&A and international expansion. “The company’s track record of identifying, developing and launching niche pharmaceutical products, coupled with H.I.G.’s international presence and history of supporting organic and acquisitive growth in its portfolio companies, underpins an exciting next chapter for Aspire,” said John Harper, managing director and head of the H.I.G. Europe Lower Middle Market LBO team.